SE7510505L - Forfarande for framstellning av ett antitumormedel - Google Patents

Forfarande for framstellning av ett antitumormedel

Info

Publication number
SE7510505L
SE7510505L SE7510505A SE7510505A SE7510505L SE 7510505 L SE7510505 L SE 7510505L SE 7510505 A SE7510505 A SE 7510505A SE 7510505 A SE7510505 A SE 7510505A SE 7510505 L SE7510505 L SE 7510505L
Authority
SE
Sweden
Prior art keywords
procedure
preparation
antitumor product
antitumor
product
Prior art date
Application number
SE7510505A
Other languages
English (en)
Inventor
D A L Davies
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of SE7510505L publication Critical patent/SE7510505L/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Metal Rolling (AREA)
  • Peptides Or Proteins (AREA)
SE7510505A 1974-09-20 1975-09-19 Forfarande for framstellning av ett antitumormedel SE7510505L (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB41037/74A GB1509707A (en) 1974-09-20 1974-09-20 Immunological compounds

Publications (1)

Publication Number Publication Date
SE7510505L true SE7510505L (sv) 1976-03-22

Family

ID=10417824

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7510505A SE7510505L (sv) 1974-09-20 1975-09-19 Forfarande for framstellning av ett antitumormedel

Country Status (7)

Country Link
JP (1) JPS5161640A (sv)
DE (1) DE2541931A1 (sv)
DK (1) DK141773B (sv)
FR (1) FR2285145A1 (sv)
GB (1) GB1509707A (sv)
NL (1) NL7511089A (sv)
SE (1) SE7510505L (sv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
JPS54132503A (en) * 1978-04-07 1979-10-15 Kayaku Antibiotic Research Co Immune globulin combined neocarcinostatin
JPS5592325A (en) * 1978-12-29 1980-07-12 Kureha Chem Ind Co Ltd Antitumor agent and its preparation
JPS5665829A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
JPS5665828A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
US4315851A (en) 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
DE3167679D1 (en) * 1980-03-31 1985-01-24 Inst Int Pathologie Cellulaire Pharmaceutical forms, their preparation and compositions containing the same
JPS58118520A (ja) * 1982-01-09 1983-07-14 Hidematsu Hirai 抗腫瘍性蛋白複合体およびその製造法
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DE3513572A1 (de) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion
JPS62228025A (ja) * 1985-12-27 1987-10-06 Teijin Ltd 抗体複合体の製造方法
WO1988007553A1 (en) * 1987-03-26 1988-10-06 Teijin Limited Process for preparing antibody complex
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
DE4122210C2 (de) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
FR2285145A1 (fr) 1976-04-16
FR2285145B1 (sv) 1980-05-30
DK141773B (da) 1980-06-16
JPS5161640A (en) 1976-05-28
GB1509707A (en) 1978-05-04
DK141773C (sv) 1980-11-03
DE2541931A1 (de) 1976-04-01
NL7511089A (nl) 1976-03-23
DK422475A (sv) 1976-03-21

Similar Documents

Publication Publication Date Title
SE437767B (sv) Forfarande for framstellning av ett antitumorlekemedel
SE7902076L (sv) Forfarande for framstellning av ihaliga gjutprodukter
SE419605B (sv) Forfarande for framstellning av undertrycksformad gjutform
SE7513085L (sv) Forfarande for framstellning av etrar
SE7510505L (sv) Forfarande for framstellning av ett antitumormedel
SE412401B (sv) Forfarande for framstellning av polyvinylpyrroliden-jod
SE410728B (sv) Forfarande for framstellning av ett oorganiskt komplex
SE7512005L (sv) Forfarande for framstellning av antitumorglykosider
SE7506160L (sv) Forfarande for framstellning av n-cykloalkylmetyldekahydroisokinoline
SE421209B (sv) Analogiforfarande for framstellning av tienobensodiazepiner
SE409452B (sv) Forfarande for framstellning av stilbenderivat
SE7506237L (sv) Forfarande for framstellning av dekahydroisokinolinderivat
NO143625C (no) Analogifremgangsmaate for fremstilling av 2-metoksy-benzamider
SE411453B (sv) Forfarande for framstellning av 3-fluorcefalosporiner
SE403477B (sv) Forfarande for famstellning av substituerade indoleniner
SE430895B (sv) Forfarande for kontinuerlig framstellning av cellulosaglykolat
SE7513739L (sv) Forfarande for framstellning av 2-scyl-4-oxo-pyrazino-isokonolin-derivat
SE7511801L (sv) Forfarande for framstellning av ympsampolymerisat
SE388854B (sv) Forfarande for framstellning av fenylpyridylaminderivat
SE7506196L (sv) Forfarande for framstellning av amidin-hydrazon-derivat
RO66137A (ro) Procedeu pentru prepararea clorhidratului de carnitina
SE401508B (sv) Forfarande for framstellning av bis(2-pyridyl-1-oxid)-disulfid
SE423815B (sv) Forfarande for framstellning av aminometylarylmetylpenicilliner
SE420097B (sv) Forfarande for framstellning av hydroxialkylxantiner
SE422679B (sv) Forfarande for framstellning av etynylbensenforeningar